Schizophrenia
Schizophrenia can affect how a person perceives reality, thinks and feels, sometimes involving hearing voices or holding unusual beliefs.
CompletedNCT00686101
Official study titleKnowledge and Perception of Smoking Risks/Consequences, Smoking Habits and Motivators for Smoking Cessation Among People With Schizophrenia
This study has finished and is no longer accepting participants.
In BaltimoreSchizophreniaObservational studyAges 18–65
- Countries
- United States
- Sponsor
- University of Maryland, Baltimore
CompletedNCT00718510
Official study titleA Randomised, Double-blind, Cross-over, Placebo Controlled, Adjunctive-treatment of L-arginine Added to Treatment-as-usual (TAU) in Schizophrenia
This study has finished and is no longer accepting participants.
In EdmontonSchizophreniaMedication studyAges 18–65
- Countries
- Canada
- Sponsor
- University of Alberta
CompletedNCT00372151
Official study titleThe Value of Augmenting L-Theanine in the Management of Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial
This study has finished and is no longer accepting participants.
Multiple locations, including BeershebaSchizophreniaPlacebo comparisonAges 18–60
- Countries
- Israel
- Sponsor
- Sha'ar Menashe Mental Health Center
TerminatedNCT00947375
Official study titleThe Effect of Lamictal TM Augmentation of Haloperidol Decanoate in the Treatment of Resistant Schizophrenia Predominantly by Verbal Resistant Hallucinosis: Randomized, Double-blind, Placebo-controlled, Study
This study ended early.
In BakuSchizophreniaMedication studyAges 18–60
- Countries
- Azerbaijan
- Sponsor
- Central Mental Clinic for Outpatients of Baku City
CompletedNCT01368406
Official study titleEfficacy of a Non-pharmacological Intervention for Weight Gain Management for Patients With Schizophrenia: Multicentric, Randomized Clinical Trial
This study has finished and is no longer accepting participants.
In São PauloSchizophreniaBehavioural studyAges 18–65
- Countries
- Brazil
- Sponsor
- Federal University of São Paulo
TerminatedNCT01943019
What is this study about?Researchers are studying Linagliptin to find out how it affects psychotic symptoms in people with schizophrenia.
This study ended early.
In Bandar Tun RazakSchizophreniaMedication studyAges 18–65
- Countries
- Malaysia
- Sponsor
- Monash University
CompletedNCT02203838
What is this study about?Researchers studied RBP-7000, tracking side effects to assess long-term safety and tolerability in people with schizophrenia.
This study has finished and is no longer accepting participants.
Multiple locations, including Little RockSchizophreniaMedication studyAges 18–65
- Countries
- United States
- Sponsor
- Indivior Inc.
CompletedNCT00216671
Official study titleEarly Versus Late Initiation of Treatment With Risperdal Consta in Subjects With Schizophrenia After an Acute Episode
This study has finished and is no longer accepting participants.
Multiple locations, including CopenhagenSchizophreniaMedication studyAges 18–65
- Countries
- France, United Kingdom, Switzerland, + 7 others
- Sponsor
- Janssen Pharmaceutica N.V., Belgium
CompletedNCT02918825
Official study titleA Randomized Trial to Compare the Efficiency and Side Effect Between Olanzapine and Long-acting Paliperidone Palmitate Injection in Schizophrenia
This study has finished and is no longer accepting participants.
In BeijingSchizophreniaMedication studyAges 18–45
- Countries
- China
- Sponsor
- Beijing HuiLongGuan Hospital
CompletedNCT02743143
Official study titleEffectiveness of 1 Year Supervised Exercise Training Versus Usual Care on Cardiovascular Health, Functional Skills and Physical Fitness in Patients With Schizophrenia
This study has finished and is no longer accepting participants.
In TrondheimSchizophreniaBehavioural studyAges 18+
- Countries
- Norway
- Sponsor
- St. Olavs Hospital
TerminatedNCT01834638
What is this study about?Researchers are studying ABT-126, tracking side effects to assess long-term safety in people with schizophrenia.
This study ended early.
Multiple locations, including ChinoSchizophreniaMedication studyAges 20–66
- Countries
- United States, United Kingdom, Russia
- Sponsor
- AbbVie
CompletedNCT01617200
What is this study about?This study evaluated the safety of Asenapine for people with schizophrenia.
This study has finished and is no longer accepting participants.
In AustinSchizophreniaMedication studyAges 18+
- Countries
- United States
- Sponsor
- Forest Laboratories